AusBiotech announced the re-appointment of Ms Julie Phillips, CEO and Executive Director of BioDiem and the re-election of Dr Andrea Douglas, Vice President, R&D Strategy and External Affairs, CSL Limited. It was further announced Ms Phillips was again appointed Chairman.
Serving as AusBiotech’s Chairman since 2014 and working in the biotechnology for more than 15 years, Ms Phillips has been a passionate and vocal advocate for the biotechnology industry. Her experience spans big pharma, regulatory affairs, clinical trials, pharmacoeconomics and start-ups. Ms Phillips is also a Director on the Board of the Medical Technologies and Pharmaceuticals Growth Centre (MTP Connect).
Ms Phillips said: “I am honoured to be re-appointed to the Board and as Chairman. The staff team and numerous committees of AusBiotech play an instrumental role in strengthening and nurturing the biotechnology and medical technology industries, and I welcome the opportunity to continue my role in guiding this valued organisation.”
Dr Douglas has held various roles at CSL since 2005 and currently overseas the global R&D strategy, product portfolio and R&D investment and prioritisation processes and is responsible for relationships with external stakeholders in the Australian medical and translational research environment. Dr Douglas also leads the Government Affairs Strategy in Australia.
The AGM was a first for CEO Glenn Cross, who took the helm of AusBiotech after former CEO Dr Anna Lavelle stepped down in September 2016.
Mr Cross said: “I look forward to working with the Board to continue the work Anna and I have been undertaking during the past decade, and to build upon this work to grow a sustainable Australian biotechnology sector.”
Serving as AusBiotech’s Chairman since 2014 and working in the biotechnology for more than 15 years, Ms Phillips has been a passionate and vocal advocate for the biotechnology industry. Her experience spans big pharma, regulatory affairs, clinical trials, pharmacoeconomics and start-ups. Ms Phillips is also a Director on the Board of the Medical Technologies and Pharmaceuticals Growth Centre (MTP Connect).
Ms Phillips said: “I am honoured to be re-appointed to the Board and as Chairman. The staff team and numerous committees of AusBiotech play an instrumental role in strengthening and nurturing the biotechnology and medical technology industries, and I welcome the opportunity to continue my role in guiding this valued organisation.”
Dr Douglas has held various roles at CSL since 2005 and currently overseas the global R&D strategy, product portfolio and R&D investment and prioritisation processes and is responsible for relationships with external stakeholders in the Australian medical and translational research environment. Dr Douglas also leads the Government Affairs Strategy in Australia.
The AGM was a first for CEO Glenn Cross, who took the helm of AusBiotech after former CEO Dr Anna Lavelle stepped down in September 2016.
Mr Cross said: “I look forward to working with the Board to continue the work Anna and I have been undertaking during the past decade, and to build upon this work to grow a sustainable Australian biotechnology sector.”
